{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:38:57Z","timestamp":1792697937842,"version":"4.5.0"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Jiangsu Province Science and Technology Plan Project \u2018Provincial Frontier Technology R&D Program\u2019","award":["BF2024054"],"award-info":[{"award-number":["BF2024054"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["OMICS: A Journal of Integrative Biology"],"abstract":"<jats:p>China has emerged as a global leader in the development and clinical translation of cutting-edge biotechnologies, including cell therapies, gene editing, and regenerative medicine. This review provides an analysis of China\u2019s landmark regulatory framework, the Regulations on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies, and examines the 112 clinical research projects that have been filed in the first nine batches under this framework. We discuss the dual-track regulatory system distinguishing new biomedical technologies from conventional drugs and medical devices. The findings demonstrate that China\u2019s approach of \u201cwide entry with strict exit\u201d and \u201cbalancing innovation with safety\u201d represents a transformative paradigm for governing frontier biomedical technologies, with significant implications for global health innovation.<\/jats:p>","DOI":"10.1177\/15578100261499496","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:54:21Z","timestamp":1792562061000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["China\u2019s Order 818: A New Commercialization Pathway Reshaping Cell and Gene Therapy"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0645-994X","authenticated-orcid":false,"given":"Jing","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-0821","authenticated-orcid":false,"given":"Lianming","family":"Liao","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Union Hospital of Fujian Medical University, Fuzhou, Fujian, China."},{"name":"TopCel KH Biotech, Jiangbei Biomedical Valley, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aek8000"},{"key":"e_1_3_3_3_1","unstructured":"Cisema. China Issues Landmark Regulation on Biomedical New Technologies. 2026. Available from: cisema.com\/news\/china-biomedical-tech-principles [Last accessed: 1August 2026]."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature.2016.20302"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01616-8"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3562"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2025.0024"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2008.0183"},{"key":"e_1_3_3_9_1","unstructured":"Sun Yat-sen University. China\u2019s New Biomedical Regulation Changes the Game. 2025. Available from: iashk.sysu.edu.cn\/en\/article\/193 [Last accessed: 1August 2026]."},{"key":"e_1_3_3_10_1","unstructured":"The European Medicines Agency. Advanced therapy medicinal products: Overview. 2026. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview [Last accessed: 30August 2026]."},{"key":"e_1_3_3_11_1","unstructured":"The National Health Commission of the People\u2019s Republic of China. Guiding Principles for the Definition of New Biomedical Technologies Pharmaceuticals and Medical Devices (Draft). 2026. Available from: www.nhc.gov.cn\/qjjys\/c100016\/202604\/48372238fd674a2da5b0c3516a4943d8.shtml [Last accessed: 1August 2026]."},{"key":"e_1_3_3_12_1","unstructured":"The National Medical Products Administration. Announcement on Optimizing of the Review and Approval Process for Clinical Trials of Innovative Drugs (No. 86). 2025. Available from: english.nmpa.gov.cn\/lawsandregulations_3.html [Last accessed: 1August 2026]."},{"key":"e_1_3_3_13_1","unstructured":"The State Council of the People\u2019s Republic of China. Healthy China 2030 Planning Outline. 2016. Available from: www.gov.cn\/zhengce\/2016-10\/25\/content_5124174.htm [Last accessed: 1August 2026]."},{"key":"e_1_3_3_14_1","unstructured":"The State Council of the People\u2019s Republic of China. 14th Five-Year Plan for National Economic and Social Development. 2021. Available from: www.gov.cn\/premier\/2021-03\/13\/content_5592681.htm [Last accessed: 1August 2026]."},{"key":"e_1_3_3_15_1","unstructured":"The State Council of the People\u2019s Republic of China. Regulations on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies (State Council Decree No. 818). 2025. Available from: www.gov.cn\/zhengce\/content\/2025-09\/28\/content_6971041.htm [Last accessed: 1August 2026]."},{"key":"e_1_3_3_16_1","unstructured":"The U.S. Food and Drug Administration. Regenerative Medicine Advanced Therapy Designation. 2026. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products [Last accessed: 30August 2026]."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.01.218"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03531-0"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10113-6"}],"container-title":["OMICS: A Journal of Integrative Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15578100261499496","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15578100261499496","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15578100261499496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:46:28Z","timestamp":1792694788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15578100261499496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":18,"alternative-id":["10.1177\/15578100261499496"],"URL":"https:\/\/doi.org\/10.1177\/15578100261499496","relation":{},"ISSN":["1536-2310","1557-8100"],"issn-type":[{"value":"1536-2310","type":"print"},{"value":"1557-8100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"article-number":"15578100261499496"}}